top of page


Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
25/09/2026 J&J’s guselkumab showed significant improvement in axial PsA FDA approved Lilly's baricitinib for sever AA in paediatric patients aged 12 and older J&J’s guselkumab showed significant improvement in axial PsA (Ref) Johnson & Johnson’s TREMFYA® (guselkumab; anti-IL-23) met its primary and major secondary endpoints in the Phase 4 STAR study in biologic-naïve adults with active psoriatic arthritis and axial involvement (axial PsA). Guselkumab significantly improved sp
decodeMR Team
Sep 291 min read
bottom of page